A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer

Trial Profile

A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs ENMD 2076 (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Sponsors CASI Pharmaceuticals
  • Most Recent Events

    • 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 07 Sep 2017 According to a CASI Pharmaceuticals media release, data from this studywill be presented at the 2017 San Antonio Breast Cancer Symposium.
    • 23 Jun 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top